Clinical study of the ability of tumour lysate pulsed dendritic cells to induce anti tumour immune responses in paediatric oncology patients
| DEC-NET Serial number GB514 | |
| Published online | 08/11/2005 16.49.00 |
| Last updated | 29/11/2005 12.10.57 |
| This trial has been approved by an ethics committee | |
| Current trial status | Open (actively recruiting new participants) |
| Major Disease (ICD9 class) | malignant neoplasm without specification of site |
| Experimental drug | |
| Autologous tumour vaccine | |
| Gender | Both |
| Age (range) | less than 18 years |
Eligibility criteria | |
| Inclusion criteria | |
| Paediatric oncology patients with relapsed or resistant disease | |
Trial design/methodology | |
| Phase | 2 |
| Kind of study | Efficacy Safety |
| Design | Controlled |
| Purpose of study | |
| It is hypothesised that administration of an autologous tumour vaccine, made from pulsing patients' dendritic cells with tumour protein, will be well tolerated and may result in the generation of anti-tumour immune responses. Outcome measure description: Tolerability of treatment protocol | |
| Primary outcomes | |
| immune anti tumour response | |
| Secondary outcomes | |
| tolerability and feasibility | |
| Principal investigator | |
| Name | Dr WJ Anderson |
| Institution | Institute of Child Health |
| Postal address | Molecular Haematology & Cancer Biology |
| City | London |
| Country | UNITED KINGDOM |
| Phone | 020 7242 9789 Ext 0190 |
| Fax | 020 7831 0488 |
| J.Anderson@ich.ucl.ac.uk | |
| Sponsor name |
| Great Ormond Street Hospital (NHS Trust) |
| ISRCTN | EudraCT |
